Evidence hub

Diabetes (Type 1 & 2): cell-therapy evidence by therapy class

Across every stem-cell intervention, ClinicalTrials.gov holds 65 registered records for Diabetes (Type 1 & 2) — 4 recruiting, 5 at Phase 3 or 4, in 23 countries. Snapshot 2026-08-29.

Medical review statusMedically reviewedReviewed by: Stem Plus medical teamReviewed on: 2026-08-29Last evidence update: 2026-08-29Methodology and editorial standards
Clinical review team: Dr Kamelia Milcheva, Hematologist · Dr Vadym Uvarov, Board-Certified Physician · Hepatobiliary Surgeon · Candidate of Medical SciencesEditorial responsibility: StemCellAtlas research teamEducational information only. This page does not provide medical advice, diagnosis or a treatment recommendation.

The condition, and why cells are proposed

The registry entries here are dominated by type 1 diabetes, an autoimmune destruction of beta cells. Two distinct strategies appear: immune reset around new-onset disease, and beta-cell replacement from stem-cell-derived islets. The second is the most genuinely transformative line of work in the whole field, and it is also the one most often invoked by clinics offering something entirely different.

Therapy classes side by side

Therapy classRegisteredRecruitingPhase 3/4Countries
MSC291311
HSCT14218
exosomes1011
PRP3203

Counts come from separate registry queries per class; a study testing two interventions can appear in more than one row, so rows do not sum to the all-interventions total.

Geography of the research

United States accounts for about 30% of country mentions among sampled studies; 23 countries host at least one site.

CountryStudies with a site there
United States17
China17
Brazil4
Canada4
United Kingdom3
Sweden3
Egypt2
Jordan2

The largest registered studies

Sorted by planned enrolment — size is not quality, but a 300-participant trial can answer questions a 12-participant series cannot.

StudyPhaseStatusPlanned nLead sponsorStart
NCT06065852 — National Registry of Rare Kidney Diseasesn/aRecruiting35,000UK Kidney Association2009-11-06
NCT04270604 — Biological Sample Collection for Research and Biobankingn/aTerminated1,279New York Stem Cell Foundation Research Institute2012-02-06
NCT05253521 — The Role of South Asian vs European Origins on Circulating Regenerative Cell Exhaustionn/aCompleted120Canadian Medical and Surgical Knowledge Translation Research2022-01-08
NCT01350219 — Stem Cell Educator Therapy in Type 1 DiabetesPhase 2Unknown100Throne Biotechnologies Inc.2010-09
NCT03562208 — Autologous Bone Marrow Transplant in Chronic Insulin Dependent Diabetic PatientsPhase 2, Phase 3Unknown100Global Cell Med2018-01-01
NCT03390231 — Stem Cell Educator Therapy in DiabetesPhase 2Unknown100Throne Biotechnologies Inc.2017-11-27

Most recently registered

StudyPhaseStatusPlanned nLead sponsorStart
NCT06938334 — A First-in-human Clinical Trial Using a Gene Therapy With Patient's Own Stem Cells to Treat Early Type 1 Diabetesn/aNot Yet Recruitingn/aAltheia Science2025-08-15
NCT06951074 — Insulin Producing Stem Cell Transplantation Clinical Trial in Type 1 Diabetesn/aRecruitingn/aAin Shams University2025-04-01
NCT06407297 — UCMSCs Combined With Standard Therapy for the Treatment of Newly Diagnosed Type 1 Diabetesn/aUnknownn/aShanghai Changzheng Hospital2024-05-23
NCT05791201 — A Safety, Tolerability, and Efficacy Study of VX-264 in Participants With Type 1 Diabetesn/aActive Not Recruitingn/aVertex Pharmaceuticals Incorporated2023-05-16
NCT04011020 — Clinical Application of Stem Cell Educator Therapy in Type 1 Diabetesn/aUnknownn/aThrone Biotechnologies Inc.2022-09-20

Reading this honestly

A registry is a plan repository. Counting entries tells you what people intended to study, which is a weaker thing than what they found. For Diabetes (Type 1 & 2) specifically, the practical question is which registered study — if any — matches the product a provider is offering, and what its outcome measures actually are.

Frequently asked

How many stem-cell trials exist for Diabetes (Type 1 & 2)?

65 registered records mention a stem-cell intervention for this condition (2026-08-29 snapshot), of which 4 were recruiting.

Which therapy class is furthest along for Diabetes (Type 1 & 2)?

Ranked by Phase 3/4 records: MSC (3), HSCT (1), exosomes (1), PRP (0).

Does a recruiting trial mean I can be treated?

No. Trials have eligibility criteria, and joining one is not the same as buying a treatment. Paying a clinic for an unproven intervention outside a registered study gives you neither the protections nor the data collection of a trial.

Registry and literature counts retrieved 2026-08-29 (ClinicalTrials.gov API v2; PubMed E-utilities). Registration or publication volume measures research activity, not effectiveness or approval. Educational information — not medical advice; verify product, indication, legal pathway and evidence with an independent qualified physician. Page generated 2026-08-29. See our editorial standards.

Explore all sections · Data & downloads

Download the query data

Download CSV · Download JSON

Query totals are full API matches; status, phase and country counts describe the first up to 400 returned records per query. Query classes overlap and must not be summed as unique trials. Counts are not treatment outcomes. Snapshot: 2026-08-29. Methods and field definitions.